Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer

Cancer Research

Volumn 73, Issue 16, 2013, Pages 5066-5079

  McGrath, Meagan J ^a   Binge, Lauren C ^a,b   Sriratana, Absorn ^a   Wang, Hong ^a   Robinson, Paul A ^a   Pook, David ^a,b   Fedele, Clare G ^a,c   Brown, Susan ^a   Dyson, Jennifer M ^a   Cottle, Denny L ^a   Cowling, Belinda S ^a,d   Niranjan, Birunthi ^a   Risbridger, Gail P ^a   Mitchell, Christina A ^a  

^a MONASH UNIVERSITY   (Australia)

^b Department of Immunology ^*  (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CALPAIN; FHL2 PROTEIN; FILAMIN; LIM PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CASTRATION RESISTANT PROSTATE CANCER; CELL NUCLEUS; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; REGULATORY MECHANISM;

EID: 84882642686     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4520     Document Type: Article

References (48)

1. Seruga B, Tannock IF. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol 2008;5:574-76.
2. Waltering KK, Urbanucci A, Visakorpi T. Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol 2012;360:38-43.
3. GregoryCW, He B, Johnson RT, FordOH,Mohler JL, French FS, et al. A mechanismfor androgen receptor-mediatedprostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315-9.
4. Muller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, et al. FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J 2000;19:359-69.
5. Kleiber K, Strebhardt K, Martin BT. The biological relevance of FHL2 in tumour cells and its role as a putative cancer target. Anticancer Res 2007;27:55-61.
6. Labalette C, Renard CA, Neuveut C, Buendia MA, Wei Y. Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and beta-catenin. Mol Cell Biol 2004;24:10689-702.
7. Yang Y, Hou H, Haller EM, Nicosia SV, Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J 2005;24:1021-32.
8. Muller JM, Metzger E, Greschik H, Bosserhoff AK, Mercep L, Buettner R, et al. The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus. EMBO J 2002;21:736-48.
9. Borczuk AC, Shah L, Pearson GDN, Walter KL, Wang L, Austin JHM, et al. Molecular signatures in biopsy specimens of lung cancer. Am J Respir Crit Care Med 2004;170:167-74.
10. Labalette C, Nouet Y, Levillayer F, Colnot S, Chen J, Claude V, et al. Deficiency of the LIM-only protein FHL2 reduces intestinal tumorigenesis in Apc mutant mice. PLoS ONE 2010;5:e10371.
11. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006;66:11341-7.
12. Heemers H, Regan K, Dehm SM, Tindall DJ. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. Cancer Res 2007;67:10592-9.
13. Popowicz GM, Schleicher M, Noegel AA, Holak TA. Filamins: promiscuous organizers of the cytoskeleton. Trends Biochem Sci 2006;31: 411-9.
14. Bedolla RG, Wang Y, Asuncion A, Chamie K, Siddiqui S, Mudryj MM, et al. Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases. Clin Cancer Res 2009;15:788-96.
15. Ozanne DM, Brady ME, Cook S, Gaughan L, Neal DE, Robson CN. Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. Mol Endocrinol 2000;14: 1618-26.
16. Wang Y, Kreisberg JI, Bedolla RG, Mikhailova M, deVere White RW, Ghosh PM. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4- 2 prostate cancer cells. Oncogene 2007;26:6061-70.
17. Mooso BA, Vinall RL, Tepper CG, Savoy RM, Cheung JP, Singh S, et al. Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing filamin A nuclear localization. Endocr Relat Cancer 2012;19:759-77.
18. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.
19. Fedele CG, Ooms LM, Ho M, Vieusseux J, O'Toole SA, Millar EK, et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci USA 2010;107:22231-6.
20. Cunningham CC, Gorlin JB, Kwiatkowski DJ, Hartwig JH, Janmey PA, Byers HR, et al. Actin-binding protein requirement for cortical stability and efficient locomotion. Science 1992;255:325-7.
21. Wixler V, Geerts D, Laplantine E, Westhoff D, Smyth N, Aumailley M, et al. The LIM-only protein DRAL/FHL2 binds to the cytoplasmic domain of several alpha and beta integrin chains and is recruited to adhesion complexes. J Biol Chem 2000;275:33669-78.
22. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev 2003;83:731-801.
23. Mammoto A, Huang S, Ingber DE. Filamin links cell shape and cytoskeletal structure to Rho regulation by controlling accumulation of p190RhoGAP in lipid rafts. J Cell Sci 2007;123:456-67.
24. Rios-Doria J, Kuefer R, Ethier SP, Day ML. Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. Cancer Res 2004;64: 7237-40.
25. Jay D, Garcia E, Lara J, Medina M, de la Luz Ibarra M. Determination of a cAMP-dependent protein kinase phosphorylation site in the Cterminal region of human endothelial actin-binding protein. Arch Biochem Biophys 2000;377:80-4.
26. Garcia E, Stracher A, Jay D. Calcineurin dephosphorylates the Cterminal region of filamin in an important regulatory site: a possible mechanism for filamin mobilization and cell signaling. Arch Biochem Biophys 2006;446:140-50.
27. Savli H, Szendroi A, Romics I, Nagy B. Gene network and canonical pathway analysis in prostate cancer: a microarray study. Exp Mol Med 2008;40:176-85.
28. Taylor RA, Toivanen R, Risbridger GP. Stem cells in prostate cancer: treating the root of the problem. Endocr Relat Cancer 2010;17: R273-R85.
29. Bostwick DG. Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 1996;78:330-6.
30. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69:16-22.
31. Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung HJ, Mudryj M. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 2007;67:9001-5.
32. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. Anovel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009;69:2305-13.
33. Loy CJ, Sim KS, Yong EL. Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. Proc Natl Acad Sci U S A 2003;100:4562-7.
34. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 2011;6:e19059.
35. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, et al. Distinct transcriptional programs mediated by the liganddependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012;72: 3457-62.
36. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 2010;107:16759-65.
37. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KAT, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013;73: 483-9.
38. Kinoshita M, Nakagawa T, Shimizu A, Katsuoka Y. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate. Int J Urol 2005;12:390-7.
39. Chen H, Libertini SJ, Wang Y, Kung H-J, Ghosh P, Mudryj M. ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines. J Biol Chem 2010;285: 2368-74.
40. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011;17: 5913-25.
41. Peacock SO, Fahrenholtz CD, Burnstein KL. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival. Mol Endocrinol 2012;26: 1967-79.
42. Mediwala SN, Sun H, Szafran AT, Hartig SM, Sonpavde G, Hayes TG, et al. The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. Prostate 2013;73: 267-77.
43. Leloup L, Wells A. Calpains as potential anti-cancer targets. Expert Opin Ther Targets 2011;15:309-23.
44. Mamoune A, Luo JH, Wells A. Calpain-2 as a target for limiting prostate cancer invasion. Cancer Res 2003;63:4632-40.
45. Wei Y, Renard CA, Labalette C, Wu Y, Levy L, Neuveut C, et al. Identification of the LIMprotein FHL2 as a coactivator of beta-catenin. J Biol Chem 2003;278:5188-94.
46. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009; 11:162-71.
47. Lakshmikuttyamma A, Selvakumar P, Kanthan R, Kanthan SC, Sharma RK. Overexpression of m-Calpain in human colorectal adenocarcinomas. Cancer Epidemiol Biomarkers Prev 2004;13:1604-9.
48. Ang C-S, Nice EC. Targeted In-Gel MRM: a hypothesis driven approach for colorectal cancer biomarker discovery in human feces. J Proteome Res 2010;9:4346-55.